
In a legal victory for Pacific Seafood, a proposed class action accusing the company of fixing the price paid to crabbers for Dungeness crab in the Pacific Northwest has been dismissed. The lawsuit, initiated in early 2023 by commercial crabber Brand Little, claimed that Pacific Seafood manipulated market prices through coercive agreements with other wholesale buyers and some crabbers.
The lead plaintiff, Brand Little, argued that Pacific Seafood gained control over crab pricing by forming “coercive combinations” with various wholesale buyers. Little’s lawsuit, filed under Section 1 of the Sherman Act, alleged that Pacific Seafood used its dominant market position and engaged in practices involving threats, intimidation, and retaliation to maintain its pricing schemes.
Related: Former Novartis Executive Sentenced to Probation for Role in Generic Drug Price-Fixing Scheme
However, Magistrate Judge Alex G. Tse of the U.S. District Court ruled that Little’s claims were insufficient. According to Bloomberg, Judge Tse stated that Little did not plausibly allege that Pacific Seafood coerced “substantially all” direct purchasers of fresh crab on the West Coast into participating in the alleged conspiracy. The judge noted the lack of evidence showing that Pacific’s actions had a broad impact on other buyers besides Little himself, despite there being approximately 1,400 Dungeness crab fishers along the U.S. West Coast, including 600 who deliver to Pacific Seafood.
Pacific Seafood, which filed a motion to dismiss the lawsuit in May 2023, argued that Little failed to demonstrate any anticompetitive or exclusionary conduct. The company also pointed out that Little did not identify any other buyers harmed by its actions.
The dismissal of the lawsuit is a temporary reprieve for Pacific Seafood, which has faced criticism and legal challenges over its market practices.
Source: News Bloomberg Law
Featured News
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Live Nation Under Criminal Antitrust Investigation Over Pandemic-Era Refund Policies
May 19, 2025 by
CPI
BCLP Strengthens Healthcare and Antitrust Litigation Practice
May 19, 2025 by
CPI
Italy Fines AI Chatbot Maker Replika €5 Million Over Privacy Violations
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas